Maggie is Vice President of ORI Capital. Maggie’s primary responsibilities include conducting science & technology due diligence as well as certain post investment portfolio activities.
Maggie has over 10 years of research experience in the field of Oncology, Degenerative Disease, Rare Congenital Disease and Drug Innovation/Development. Maggie was a postdoctoral research fellow of the School of Biomedical Sciences, the University of Hong Kong from 2015 to 2018 and was a postdoctoral research fellow of the Department of Biochemistry, the University of Hong Kong from 2005 to 2015.
Maggie received a BS in Life Science from Fudan University and a PhD from the City University of Hong Kong.